European stocks edged higher on Friday, led by upbeat corporate earnings and a jump in Novo Nordisk shares, and were set for ...

(Reuters) -European shares edged higher and were on track for their biggest weekly gain in 12 as investors assessed U.S.

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares. Donald Trump's executive order changing 401 ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The mini tender offer is for the purchase of up to 2 million American Depositary shares representing less than 0.045% of its ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...